Drug intelligence / Profile preview

PN-232

Development stage: Phase 1
Lead developer: Janssen Biotech
Modality: Small Molecules, Peptides
Administration: Oral

Overview

PN-232 is a second-generation, oral peptide drug that acts as an interleukin-23 receptor (IL-23R) antagonist. It was developed as a gastrointestinal-restricted therapy intended to block the IL-23 pathway by inhibiting the IL-23 receptor. The drug was designed for potential use in diseases mediated by the IL-23 pathway and was being co-developed by Protagonist Therapeutics and Janssen Research & Development (a Johnson & Johnson company). Clinical development reached Phase 1 trials in healthy volunteers but has since been discontinued[2][3][5].

Other names: PN 232PN232PN-232

Targets

IL23R (Interleukin-23 Receptor)

Beyond the preview

Go deeper on PN-232.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PN-232.

Explore the full profile